section name header

Pronunciation ⬇

soo-KRAL-fate audio

Classifications ⬆ ⬇

Therapeutic Classification: antiulcer agents

Pharmacologic Classification: gi protectants

Indications ⬆ ⬇

REMS

Unlabeled Use:

Action ⬆ ⬇

Therapeutic Effects:

Pharmacokinetics ⬆ ⬇

Absorption: Systemic absorption is minimal (<5%).

Distribution: Unknown.

Metabolism/Excretion: >90% is eliminated in the feces.

Half-life: 6–20 hr.

Time/Action Profile ⬆ ⬇

(mucosal protectant effect)

ROUTEONSETPEAKDURATION
PO1–2 hrunknown6 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: pruritus, rash.

Endo: hyperglycemia (with suspension).

GI: constipation, diarrhea, dry mouth, gastric discomfort, indigestion, nausea.

Neuro: dizziness, drowsiness.

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).

Interactions ⬆ ⬇

Drug-Drug:

Route/Dosage ⬆ ⬇

Treatment of Ulcers

Gastroesophageal Reflux

Stomatitis

Proctitis

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Carafate

Canadian Brand Names ⬆ ⬇

Cytogard, Sulcrate, Sulcrate Plus

Code ⬆

NDC Code*